A Todd
Patients with advanced lung cancer: is there scope to discontinue inappropriate medication?
Todd, A; Williamson, S; Husband, A; Baqir, W; Mahoney, M
Authors
S Williamson
A Husband
W Baqir
M Mahoney
Abstract
Polypharmacy—taking five or medications per day—is common in lung cancer patients. This patient group is prescribed medication to control acute symptoms associated with cancer and also to prevent or treat other long-term conditions. These medications increase the pill burden for the patient and also the probability of developing a drug-related toxicity. Objective To assess the prevalence of inappropriate medication in patients taking erlotinib for the treatment of advanced non-small cell lung cancer. Method This was a multicentre study across three sites in the North of England. Medication histories for patients receiving erlotinib were retrospectively extracted from medical notes and assessed by the clinical team (a consultant pharmacist, nurse specialist and clinical oncologist) to determine if the medication was appropriate or inappropriate. The clinical team considered the following factors when deciding if the medication was appropriate or inappropriate: remaining life expectancy of the patient, time until benefit of the treatment, goals of care and treatment targets. Results Among the 20 patients assessed, 19 (95 %) according to the clinical team were taking medications that were inappropriate. The mean number of medications the patients were taking was 8 (range 1–16) and the most common class of medication used were drugs affecting the Central Nervous System. In addition, there were 11 patients (55 %) who were taking erlotinib in combination with a proton pump inhibitor (PPI)—a clinically significant drug interaction that impairs the absorption of erlotinib. Conclusions Patients taking erlotinib for the treatment of advanced non-small cell lung cancer take many inappropriate medications for the treatment or prevention of long-term conditions. These patients should have their medications reviewed in the context of their original therapeutic goals.
Citation
Todd, A., Williamson, S., Husband, A., Baqir, W., & Mahoney, M. (2013). Patients with advanced lung cancer: is there scope to discontinue inappropriate medication?. International Journal of Clinical Pharmacy, 35(2), 181-184. https://doi.org/10.1007/s11096-012-9731-2
Journal Article Type | Article |
---|---|
Publication Date | Apr 1, 2013 |
Deposit Date | Mar 4, 2013 |
Publicly Available Date | Oct 23, 2013 |
Journal | International Journal of Clinical Pharmacy |
Print ISSN | 2210-7703 |
Electronic ISSN | 2210-7711 |
Publisher | Springer |
Peer Reviewed | Peer Reviewed |
Volume | 35 |
Issue | 2 |
Pages | 181-184 |
DOI | https://doi.org/10.1007/s11096-012-9731-2 |
Keywords | Erlotinib, Inappropriate medication, Limited life expectancy, Lung cancer, Medication review, Polypharmacy. |
Files
Accepted Journal Article
(486 Kb)
PDF
Copyright Statement
The final publication is available at Springer via http://dx.doi.org/10.1007/s11096-012-9731-2.
You might also like
The Role of Patient Preferences in Deprescribing
(2017)
Journal Article
Safety profile of lamotrigine in overdose
(2016)
Journal Article
Downloadable Citations
About Durham Research Online (DRO)
Administrator e-mail: dro.admin@durham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search